Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_assertion type Assertion NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_head.
- NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_assertion description "[Examples are discussed for each category, and 1 example of each category is named here: 1) total ablation of the entire tissue with effort to replace ablated functions (for example, in C-cell neoplasia of multiple endocrine neoplasia type 2); 2) subtotal ablation with increased likelihood of persistent disease or recurrent disease (for example, in the parathyroid tumors of MEN1); or 3) no ablation of tissue with or without the use of pharmacotherapy (for example, with blockers for secretion of stomach acid in gastrinomas of MEN1).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_provenance.
- NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_assertion evidence source_evidence_literature NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_provenance.
- NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_assertion SIO_000772 23771922 NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_provenance.
- NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_assertion wasDerivedFrom befree-2016 NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_provenance.
- NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_assertion wasGeneratedBy ECO_0000203 NP1086437.RAmikqY0bu2d4hyR5fJZH2591GSyIE4rJ07-Xq6utO6vY130_provenance.